Search research articles
Contact Us
Filters
Showing results (361-370 of 391) with videos related to
Page
of 40
Sort By:
The Lancet. Oncology
|
December 25, 2025
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial
Karim Fizazi, Fred Saad, Teresa Alonso-Gordoa, et al.
Urology Practice
|
February 27, 2023
An Assessment Tool to Provide Targeted Feedback to Robotic Surgical Trainees: Development and Validation of the End-To-End Assessment of Suturing Expertise (EASE)
Taseen F Haque, Alvin Hui, Jonathan You, et al.
Urology Practice
|
May 3, 2023
Development and validation of an objective scoring tool to evaluate surgical dissection: Dissection Assessment for Robotic Technique (DART)
Erik B Vanstrum, Runzhuo Ma, Jacqueline Maya-Silva, et al.
Gynecologic Oncology
|
August 31, 2020
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma
Nicoletta Colombo, Amit M Oza, Domenica Lorusso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2012
Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group
Winnie Yeo, Hyun C Chung, Stephen L Chan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 23, 2015
Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies
A L Wong, R A Soo, D S Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 2, 2026
Neoadjuvant nivolumab with or without ipilimumab for cisplatin-ineligible patients with muscle-invasive bladder cancer
Brendan J Guercio, Eugene J Pietzak, Vignesh Ravichandran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2020
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma
Amit M Oza, Domenica Lorusso, Carol Aghajanian, et al.
The Lancet. Oncology
|
March 1, 2023
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
Toni K Choueiri, Masatoshi Eto, Robert Motzer, et al.
Journal for Immunotherapy of Cancer
|
August 17, 2022
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
Karim Fizazi, Margitta Retz, Daniel P Petrylak, et al.
Page
of 40
Search research articles
Search
Showing results (361-370 of 391) with videos related to
Sort By:
Page
of 40
The Lancet. Oncology
|
December 25, 2025
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial
Karim Fizazi, Fred Saad, Teresa Alonso-Gordoa, et al.
Urology Practice
|
February 27, 2023
An Assessment Tool to Provide Targeted Feedback to Robotic Surgical Trainees: Development and Validation of the End-To-End Assessment of Suturing Expertise (EASE)
Taseen F Haque, Alvin Hui, Jonathan You, et al.
Urology Practice
|
May 3, 2023
Development and validation of an objective scoring tool to evaluate surgical dissection: Dissection Assessment for Robotic Technique (DART)
Erik B Vanstrum, Runzhuo Ma, Jacqueline Maya-Silva, et al.
Gynecologic Oncology
|
August 31, 2020
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma
Nicoletta Colombo, Amit M Oza, Domenica Lorusso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2012
Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group
Winnie Yeo, Hyun C Chung, Stephen L Chan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 23, 2015
Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies
A L Wong, R A Soo, D S Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 2, 2026
Neoadjuvant nivolumab with or without ipilimumab for cisplatin-ineligible patients with muscle-invasive bladder cancer
Brendan J Guercio, Eugene J Pietzak, Vignesh Ravichandran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2020
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma
Amit M Oza, Domenica Lorusso, Carol Aghajanian, et al.
The Lancet. Oncology
|
March 1, 2023
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
Toni K Choueiri, Masatoshi Eto, Robert Motzer, et al.
Journal for Immunotherapy of Cancer
|
August 17, 2022
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
Karim Fizazi, Margitta Retz, Daniel P Petrylak, et al.
Page
of 40